C.12.02 Translating symptoms via neurobiology (English)
In:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
;
15
;
S663
;
2005
-
ISSN:
- Article (Journal) / Print
-
Title:C.12.02 Translating symptoms via neurobiology
-
Published in:EUROPEAN NEUROPSYCHOPHARMACOLOGY ; 15 ; S663
-
Publisher:
- New search for: Elsevier Science B.V., Amsterdam.
-
Publication date:2005-01-01
-
Size:S663
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.8 / 615.1
- Further information on Dewey Decimal Classification
-
Classification:
-
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 15
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Low GSK-3b in schizophrenia as a consequence of neurodevelopmental insultKozlovsky, N. / Nadri, C. / Agam, G. et al. | 2005
- 13
-
Amantadine for weight gain associated with olanzapine treatmentDeberdt, W. / Winokur, A. / Cavazzoni, P. A. / Trzaskoma, Q. N. / Carlson, C. D. / Bymaster, F. P. / Wiener, K. / Floris, M. / Breier, A. et al. | 2005
- 23
-
Chlorpromazine and loxapine reduce interleukin-1b and interleukin-2 release by rat mixed glial and microglial cell culturesLabuzek, K. / Kowalski, J. / Gabryel, B. / Herman, Z. S. et al. | 2005
- 31
-
Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitizationLesscher, H. M. / Hoogveld, E. / Burbach, J. P. / van Ree, J. M. / Gerrits, M. A. et al. | 2005
- 39
-
Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisiaJanno, S. / Holi, M. M. / Tuisku, K. / Wahlbeck, K. et al. | 2005
- 43
-
Intrahippocampal nicotine in alcohol drinking rats-effects on lever-press responseGarcia-Rebollo, Y. / Darbra, S. / Nuria, F. et al. | 2005
- 51
-
No association of clock gene T3111C polymorphism and affective disordersBailer, U. / Wiesegger, G. / Leisch, F. / Fuchs, K. / Leitner, I. / Letmaier, M. / Konstantinidis, A. / Stastny, J. / Sieghart, W. / Hornik, K. et al. | 2005
- 57
-
Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated miceKurosaki, R. / Muramatsu, Y. / Kato, H. / Watanabe, Y. / Imai, Y. / Itoyama, Y. / Araki, T. et al. | 2005
- 69
-
Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled studyErzegovesi, S. / Guglielmo, E. / Siliprandi, F. / Bellodi, L. et al. | 2005
- 75
-
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidolSmulevich, A. B. / Khanna, S. / Eerdekens, M. l. / Karcher, K. / Kramer, M. / Grossman, F. et al. | 2005
- 85
-
Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in miceZuchora, B. / Wielosz, M. / Urbanska, E. M. et al. | 2005
- 95
-
The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidateCheon, K. A. / Ryu, Y. H. / Kim, J. W. / Cho, D. Y. et al. | 2005
- 103
-
Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanismsDaniel, W. A. / Haduch, A. / Wojcikowski, J. et al. | 2005
- 111
-
Comparative efficacy and safety of long-acting risperidone and risperidone oral tabletsChue, P. / Eerdekens, M. / Augustyns, I. / Lachaux, B. / Mol�?an, P. / Eriksson, L. / Pretorius, H. / David, A. S. et al. | 2005
- 119
-
Antidepressants attenuate both the enhanced ethanol intake and ethanol-induced anxiolytic effects in diazepam withdrawn ratsMartijena, I. D. / Bustos, S. G. / Bertotto, M. E. / Molina, V. A. et al. | 2005
- 249
-
Urinary excretion of biopyrrins, oxidative metabolites of bilirubin, increases in patients with psychiatric disordersMiyaoka, T. / Yasukawa, R. / Yasuda, H. / Shimizu, M. / Mizuno, S. / Sukegawa, T. / Inagaki, T. / Horiguchi, J. et al. | 2005
- 253
-
The involvement of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks in an animal model of depressionMaayan, R. / Morad, O. / Dorfman, P. / Overstreet, D. H. / Weizman, A. / Yadid, G. et al. | 2005
- 263
-
Pharmacokinetic comparison of two methods of heroin smoking: ‘chasing the dragon’ versus the use of a heating deviceKlous, M. G. / Huitema, A. D. / Rook, E. J. / Hillebrand, M. J. / Hendriks, V. M. / Van den Brink, W. / Beijnen, J. H. / Van Ree, J. M. et al. | 2005
- 271
-
Haloperidol treatments increased macrophage activity in male and female rats: influence of corticosterone and prolactin serum levelsLourenço, G. A. / Dorce, V. A. / Palermo-Neto, J. et al. | 2005
- 279
-
Anxiogenic effects of Sumatriptan in panic disorder: A double-blind, placebo-controlled studyAmital, D. / Fostick, L. / Sasson, Y. / Kindler, S. / Amital, H. / Zohar, J. et al. | 2005
- 283
-
Chronic administration of the SSRI fluvoxamine markedly and selectively reduces the sensitivity of cortical serotonergic neurons to footshock stressDazzi, L. / Seu, E. / Cherchi, G. / Biggio, G. et al. | 2005
- 291
-
Nutritional and life style determinants of plasma homocysteine in schizophrenia patientsStahl, Z. / Belmaker, R. H. / Friger, M. / Levine, J. et al. | 2005
- 297
-
Reinstatement of cocaine-seeking behavior in rats is attenuated following repeated treatment with the opioid receptor antagonist naltrexoneGerrits, M. A. / Kuzmin, A. V. / van Ree, J. M. et al. | 2005
- 305
-
Lowered DHEA-S plasma levels in adult individuals with autistic disorderStrous, R. D. / Golubchik, P. / Maayan, R. / Mozes, T. / Tuati-Werner, D. / Weizman, A. / Spivak, B. et al. | 2005
- 311
-
Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brainAngelucci, F. / Aloe, L. / Iannitelli, A. / Gruber, S. H. / Mathé, A. A. et al. | 2005
- 319
-
The possible role of neurotrophins in the pathogenesis and therapy of schizophreniaShoval, G. / Weizman, A. et al. | 2005
- 331
-
Rats with scopolamine- or MK-801-induced spatial discrimination deficits in the cone field task: animal models for impaired spatial orientation performanceBouger, P. C. / van der Staay, F. J. et al. | 2005
- 347
-
Possible association between the gamma-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophreniaZai, G. / King, N. / Wong, G. W. / Barr, C. L. / Kennedy, J. L. et al. | 2005
- 355
-
Towards a better understanding of the size and burden and cost of brain disorders in EuropeWittchen, H. U. / Jönsson, B. / Olesen, J. et al. | 2005
- 357
-
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studiesWittchen, H. U. / Jacobi, F. et al. | 2005
- 377
-
Alcohol use disorders in EU countries and Norway: An overview of the epidemiologyRehm, J. r. / Room, R. / van den Brink, W. / Jacobi, F. et al. | 2005
- 389
-
Problematic drug use and drug use disorders in EU countries and Norway: An overview of the epidemiologyRehm, J. r. / Room, R. / van den Brinkt, W. / Kraus, L. et al. | 2005
- 399
-
Size of burden of schizophrenia and psychotic disordersRössler, W. / Joachim Salize, H. / van Os, J. / Riecher-Rössler, A. et al. | 2005
- 411
-
Size and burden of depressive disorders in EuropePaykel, E. S. / Brugha, T. / Fryers, T. et al. | 2005
- 425
-
Prevalence and burden of bipolar disorders in European countriesPini, S. / de Queiroz, V. r. / Pagnin, D. / Pezawas, L. / Angst, J. / Cassano, G. B. / Wittchen, H. U. et al. | 2005
- 435
-
The epidemiology of panic disorder and agoraphobia in EuropeGoodwin, R. D. / Faravelli, C. / Rosi, S. / Cosci, F. / Truglia, E. / de Graaf, R. / Wittchen, H. U. et al. | 2005
- 445
-
The epidemiology of generalized anxiety disorder in EuropeLieb, R. / Becker, E. / Altamura, C. et al. | 2005
- 453
-
Size and burden of social phobia in EuropeFehm, L. / Pelissolo, A. / Furmark, T. / Wittchen, H. U. et al. | 2005
- 463
-
Prevalence of dementia in the elderly in EuropeBerr, C. / Wancata, J. / Ritchie, K. et al. | 2005
- 473
-
Prevalence and incidence of Parkinson's disease in Europevon Campenhausen, S. / Bornschein, B. / Wick, R. / Bötzel, K. / Sampaio, C. / Poewe, W. / Oertel, W. / Siebert, U. / Berger, K. / Dodel, R. et al. | 2005
- 491
-
No implication of brain-derived neurotrophic factor (BDNF) gene in unipolar affective disorder: Evidence from Belgian first and replication patient–control studiesOswald, P. / Del-Favero, J. / Massat, I. / Souery, D. / Claes, S. / Van Broeckhoven, C. / Mendlewicz, J. et al. | 2005
- 497
-
Hydrosoluble fiber (Plantago ovata husk) and levodopa I: Experimental study of the pharmacokinetic interactionGarcia, J. J. / Fernandez, N. / Carriedo, D. / Diez, M. J. / Sahagun, A. / Gonzalez, A. / Calle, A. / Sierra, M. et al. | 2005
- 505
-
Hydrosoluble fiber (Plantago ovata husk) and levodopa II: Experimental study of the pharmacokinetic interaction in the presence of carbidopaFernandez, N. / Carriedo, D. / Sierra, M. / Diez, M. J. / Sahagun, A. / Calle, A. / Gonzalez, A. / Garcia, J. J. et al. | 2005
- 511
-
In search of anticipation in unipolar affective disorderPapadimitriou, G. N. / Souery, D. / Lipp, O. / Massat, I. / Mahieu, B. / Van Broeckhoven, C. / Mendlewicz, J. et al. | 2005
- 517
-
Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2Schou, M. / Halldin, C. / Pike, V. W. / Mozley, P. D. / Dobson, D. / Innis, R. B. / Farde, L. / Hall, H. k. et al. | 2005
- 521
-
SERT and DAT availabilities under citalopram treatment in obsessive–compulsive disorder (OCD)Pogarell, O. / Poepperl, G. / Mulert, C. / Hamann, C. / Sadowsky, N. / Riedel, M. / Moeller, H. J. / Hegerl, U. / Tatsch, K. et al. | 2005
- 525
-
Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophreniaMüller, D. J. / De Luca, V. / Sicard, T. / King, N. / Hwang, R. / Volavka, J. / Czobor, P. / Sheitman, B. B. / Lindenmayer, J. P. / Citrome, L. et al. | 2005
- 533
-
Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometryArnold, O. / Saletu, B. / Anderer, P. / Assandri, A. / di Padova, C. / Corrado, M. / Saletu-Zyhlarz, G. M. et al. | 2005
- 545
-
Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCNTuma, J. / Strubbe, J. H. / Mocaër, E. / Koolhaas, J. M. et al. | 2005
- 557
-
Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patientsSchwartz, K. / Iancu, I. / Stryjer, R. / Chelben, J. / Kotler, M. / Weizman, A. / Rehavi, M. et al. | 2005
- 563
-
Antidepressant-like effects of selegiline in the forced swim testShimazu, S. / Minami, A. / Kusumoto, H. / Yoneda, F. et al. | 2005
- 573
-
Quetiapine or haloperidol as monotherapy for bipolar mania—a 12-week, double-blind, randomised, parallel-group, placebo-controlled trialMcIntyre, R. S. / Brecher, M. / Paulsson, B. r. / Huizar, K. / Mullen, J. et al. | 2005
- 587
-
Effects of phencyclidine on acoustic startle and prepulse inhibition in neuronal nitric oxide synthase deficient miceKlamer, D. / Engel, J. r. / Svensson, L. et al. | 2005
- 593
-
Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim testHill, M. N. / Gorzalka, B. B. et al. | 2005
- 601
-
Clozapine improves working memory updating in schizophreniaGalletly, C. A. / Clark, C. R. / McFarlane, A. C. et al. | 2005
- 609
-
Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in miceLuszczki, J. J. / Andres, M. M. / Czuczwar, P. / Cioczek-Czuczwar, A. / Wojcik-Cwikla, J. / Ratnaraj, N. / Patsalos, P. N. / Czuczwar, S. J. et al. | 2005
- 617
-
Deramciclane in the treatment of generalized anxiety disorder: A placebo-controlled, double-blind, dose-finding studyNaukkarinen, H. / Raassina, R. / Penttinen, J. / Ahokas, A. / Jokinen, R. / Koponen, H. / Lepola, U. / Kanerva, H. / Lehtonen, L. / Pohjalainen, T. et al. | 2005
- 625
-
Nicotine increases microdialysate brain amino acid concentrations and induces conditioned place preferenceKashkin, V. A. / De Witte, P. et al. | 2005
- 633
-
Valproate attenuates dextroamphetamine-induced subjective changes more than lithiumWillson, M. C. / Bell, E. C. / Dave, S. / Asghar, S. J. / McGrath, B. M. / Silverstone, P. H. et al. | 2005
- 641
-
No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomesLieb, K. / Fiebich, B. L. / Herpfer, I. / Mantovani, M. / Löffler, M. / Feuerstein, T. J. et al. | 2005
- 647
-
Circulatory neurosteroid levels in underweight female adolescent anorexia nervosa inpatients and following weight restorationStein, D. / Maayan, R. / Ram, A. / Loewenthal, R. / Achiron, A. / Modan-Moses, D. / Feigin, M. / Weizman, A. / Valevski, A. et al. | 2005
- 655
-
Dissociation between the locomotor and anxiolytic effects of acetaldehyde in the elevated plus-maze: Evidence that acetaldehyde is not involved in the anxiolytic effects of ethanol in miceTambour, S. / Didone, V. / Tirelli, E. / Quertemont, E. et al. | 2005
- 663
-
Subjective and neurovegetative changes in healthy volunteers and panic patients performing simulated public speakingParente, A. C. / Garcia-Leal, C. / Del-Ben, C. M. / Guimarães, F. S. / Graeff, F. G. et al. | 2005
- 673
-
Pharmacological modulation of cholinergic brain activity and its reflection in special EEG frequency ranges from various brain areas in the freely moving rat (Tele-Stereo-EEG)Dimpfel, W. et al. | 2005
- 683
-
Author Index (Volume 15)| 2005
- 689
-
Key Word Index (Volume 15)| 2005
- I
-
Instructions to Authors| 2005
- S1
-
S.1.1 Genetic approaches to psychiatricdiseasesGoldman, D. et al. | 2005
- S2
-
S.1.2 Molecular concepts: histone modificationsto investigate the impact of stress on the brainReul, J. M. / Droste, S. K. / Chandramohan, Y. et al. | 2005
- S3
-
P.1.01 Schizophrenia-associated-proteins ina neurodevelopmentally rat model of schizophreniaCarmit, N. / Lipska, B. K. / Belmaker, R. H. / Agam, G. et al. | 2005
- S4
-
P.1.02 The effect of chronic lithium and lithium withdrawal on ventral tegmental area dopaminergic functionFerrie, L. J. / Martin, C. M. / Young, A. H. / Gartside, S. E. / McQuade, R. et al. | 2005
- S5
-
P.1.03 N-terminal domain of Wolframin interactswith carboxypeptidase ELuuk, H. / Tools, U. / Kô / ks, S. / Vasar, E. et al. | 2005
- S6
-
P.1.05 Benzodiazepine-adrenergic receptorinteractions in the pathophysiology of major depressionMinenko, S. et al. | 2005
- S8
-
P.1.07 Glutamatergic aspects of psychosis in neurodevelopmental animal model: What can they teach us about schizophrenia?Skuba, I. / t'astý / E. et al. | 2005
- S10
-
P.1.10 Effect of St. John's wort (Hypericumperforatum) on cytochrome P-450 2C6, 2D2 and 3A1/2 in ratsDostalek, M. / Pistovcakova, J. / Jurica, J. / Tomandl, J. / Linhart, I. / Sulcová / A. / Hadasova, E. et al. | 2005
- S11
-
P.1.11 Hyperforin inhibits serotonin uptake by activating non selective cation channelsTreiber, K. / Singer, A. / Henke, B. / Mü / ller, W. E. et al. | 2005
- S12
-
P.1.13 Hyperactivity and altered dopaminergicfunction in FGF-2 knockout miceBedogni, E. / Fadda, P. / Fresu, A. / Racagni, G. / Riva, M. A. et al. | 2005
- S13
-
P.1.14 Modulation of the mesocortical dopaminergic system by prefrontal 5-HT1A receptors. Role in antipsychotic drug actionBortolozzi, A. / Scorza, M. C. / Dí / az-Mataix, L. / Celada, E. / Toth, M. / Artigas, F. et al. | 2005
- S14
-
P.1.16 Novelty induces phosphorylation and phospho-acetylation of histone H3 in rat dentate gyrus granule neuronsChandramohan, Y. / Droste, S. K. / Reul, J. M. et al. | 2005
- S15
-
P.1.17 Regulation of synaptic transmission inthe striatum by protein kinasesChergui, K. et al. | 2005
- S16
-
P.1.19 The role of brain derived neurotropic factor (BDNF) in anorexia nervosa and hyperactivityde Krom, M. / Hillebrand, J. / Hendriks, J. / van Elburg, A. / Adan, R. et al. | 2005
- S17
-
P.1.20 Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by exogenous 5-HT1A receptor activationDí / az-Mataix, L. / Celada, P. / Artigas, F. et al. | 2005
- S18
-
P.1.21 Chronic antidepressant treatments reduce glutamate release and protein-protein interactions favoring formation of snare complexPopoli, M. / Giambelli, R. / Raiteri, L. / Tiraboschi, E. / Musazzi, L. / Barbiero, V. / Raiteri, M. / Racagni, G. / Bonanno, G. et al. | 2005
- S20
-
P.1.24 A transmembrane calcium flux is requiredfor circadian clock gene rhythmicity in mammalian pacemaker neuronsLundkvist, G. / Kwak, Y. / Davis, E. / Tei, H. / Block, G. et al. | 2005
- S21
-
P.1.25 Galantamine increases firing activity of dopaminergic neurons in the ventral tegmental areaSchilströ / m, B. / Ivanov, V. / Wiker, C. / Svensson, T. H. et al. | 2005
- S22
-
P.1.27 An endogenous compound 1-methyl-1,2,3,4-tetrahydroisoquinolineprevents the morphine addiction in rat: the view on neurochemical mechanism of actionWą / sik, A. / Patsenka, A. / Antkiewicz-Michaluk, L. et al. | 2005
- S23
-
P.1.28 Excitatory effects of thyrotropin-releasing hormone (TRH) in the thalamus: evidence for a role in the switch between sleep and wakingBroberger, C. et al. | 2005
- S24
-
P.1.29 Subtype dependent changes of α1-adrenoceptormRNAs expression in the rat prefrontal cortex induced by the chronic mild stress procedureBielawski, A. / Zelek-Molik, A. / Papp, M. / Nalepa, I. et al. | 2005
- S25
-
P.1.31 Constitutive dimerization of the histamineH3 receptor in living cellsMorisset, S. / Chabret, C. / Arrang, J. M. et al. | 2005
- S26
-
P.1.32 Association between the serotonin transporter linked polymorphic region gene and response to tricyclic antidepressantsTsapakis, E. / Checkley, S. / Kerwin, R. W. / Aitchison, K. J. et al. | 2005
- S29
-
S.2.1 Behavioral correlates of neurotransmitterfunction in depressionArtigas, F. et al. | 2005
- S30
-
S.2.2 Neuropsychopharmacology: bridginganimal and human studiesBlier, P. et al. | 2005
- S32
-
P.2.02 The 5-HT1A and GABAA-benzodiazepine receptors: Effects in behavior and pharmacology in female 5-HT1A knockout miceVan Bogaert, M. J. / Gerritsen, L. / Groenink, L. / Oosting, R. S. / Olivier, B. et al. | 2005
- S33
-
P.2.03 Effect of urocortin 2 on home cagebehaviors and serotonergic neurons in the dorsal raphe nucleusStaub, D. R. / Spiga, E. / Lowry, C. A. et al. | 2005
- S34
-
P.2.05. Rats reared in social isolation displaydisrupted ppi and elevated levels of kynurenic acid in the hippocampusErhardt, S. / Powell, S. B. / Nilsson, L. K. / Linderholm, K. R. / Swerdlow, N. R. / Geyer, M. A. et al. | 2005
- S35
-
P.2.06 Central activation of corticotropin-releasing factor receptor type 1 and type 2 receptors results in distinct serotonergic, neuroendocrine and behavioural responsesde Groote, L. / Flachskamm, C. / Peñ / alva, R. G. / Reul, J. M. / Linthorst, A. C. et al. | 2005
- S36
-
P.2.07 Selecting over-active extremes in outbred heterogeneous stock (HS) mice for gene expression profiling: nominating novel candidate genes for over-activityLiu, L. / Fernandes, C. / Brookes, K. / Paya-Capo, J. / Asherson, P. / Schalkwyk, L. C. et al. | 2005
- S38
-
P.2.10 Discriminative stimulus propertiesof tianeptine: partial substitution by fluoxetine and 8-OH-DPATAlici, T. / Kayir, H. / Aygoren, M. O. / Saglam, E. / Uzbay, I. T. et al. | 2005
- S39
-
P.2.11 Crossbreeding studies with helpless “HIRouen” and “NH/Rouen” indicate that some phenotypic differences between the lines are related to the helpless traitEl Yacoubi, M. / Popa, D. / Martin, B. / Hamon, M. / Costentin, J. / Adrien, J. / Vaugeois, J. M. et al. | 2005
- S40
-
P.2.12 Pharmacological validation of the mouse elevated horizontal rod (the Suok test) as a novel experimental model of anxiety: sensitivity to diazepam and pentylenetetrazoleKalueff, A. V. / Tuohimaa, P. et al. | 2005
- S41
-
P.2.14 Influence of NMDA-receptors blockator on the sleep-wakefulness cycle in catsMchedlidze, O. / Menteshashvili, N. / Gogichadze, M. / Lortkipanidze, N. / Chidjavadze, E. / Beritashvili, L. et al. | 2005
- S42
-
P.2.15 Kynurenic acid andN-acetylaspartylglutamate do not alter PPI in micePå / lsson, E. / Klamer, D. / Revesz, A. / Engel, J. A. / Svensson, L. et al. | 2005
- S44
-
P.2.18 Altered physiological responses to stress in the olfactory bulbectomised rat: normalisation by chronic fl uoxetine treatmentRoche, M. / Harkin, A. / Kelly, J. P. et al. | 2005
- S45
-
P.2.19 GABAB receptor positive modulation as a novel therapeutic approach to drug dependence: blockade of the rewarding and psychostimulant effects of cocaineSlattery, D. A. / Mombereau, C. / Froestl, W. / Markou, A. / Kaupmann, K. / Cryan, J. F. et al. | 2005
- S46
-
P.2.20 c-fos mRNA expression within the ratbrain after exposure to the elevated plus maze: effect of prior treatment with anxiogenic and anxiolytic drugsTroakes, C. / Ingram, C. D. et al. | 2005
- S47
-
P.2.22 Strain related gender differences incortical 5-HT autoreceptor responses to sub-chronic fluoxetineShalom, G. / Lifshytz, T. / Gur, E. / Lerer, B. / Newman, M. E. et al. | 2005
- S48
-
P.2.23 Evidence for social recognition inC57BL/6J and A/J miceMalyshkin, A. A. / Zvartau, E. E. / Van Ree, J. M. / Kas, M. J. et al. | 2005
- S49
-
P.2.25 Characterisation of a caffeine-inducedmodel of insomnia in the ratPaterson, L. M. / Ivarsson, M. / Hutson, P. H. et al. | 2005
- S51
-
S.3.2 Endophenotypes for affective disordersModell, S. et al. | 2005
- S52
-
P.3.01 Neurocognitive impairment in euthymic young adults with recurrent depression: a case-control comparison of major depression and bipolar-spectrum disorderSmith, D. J. / Muir, W. J. / Blackwood, D. H. et al. | 2005
- S53
-
P.3.02 The time course of neuropsychiatric symptoms induced by pegylated interferon-alpha-2b and ribavirin treatment for hepatitis C: a follow-up studyBull, S. J. / Maddock, C. / Landau, S. / Barry, K. / Maulayah, P. / Hotopf, M. / Cleare, A. / Norris, S. / Pariante, C. et al. | 2005
- S54
-
P.3.03 Poststroke depression — diagnosis and treatmentDjokic, G. / Zivkovic, N. / Dostanie, A. / Milivojevic, S. et al. | 2005
- S55
-
P.3.05 Association and haplotype analaysis of90 single-nucleotide polymorphisms in mood disordersMaron, E. / Kõ / ks, S. / Nikopensius, T. / Ahmä / e, S. / Heinaste, E. / Vabrit, K. / Tammekivi, V. / Hallast, E. et al. | 2005
- S56
-
P.3.06 A glycogen synthase kinase 3-ß -50 T/CSNP influences long-term response to lithium salts in bipolar illnessPontiggia, A. / Bemasconi, A. / Benedetti, E. / Serretti, A. / Lorenzi, C. / Colombo, C. / Smeraldi, E. et al. | 2005
- S57
-
P.3.07 Antipsychotic agents and neuromusculardysfunctionReznik, I. / Volchek, L. / Reznik, M. / Weizman, A. / Meltzer, H. Y. et al. | 2005
- S58
-
P.3.09 Comparison of bone metabolism between patients with restrictive and bulimic type of anorexia nervosamiech, A. / Rabe-Jabł / oń / ska, J. et al. | 2005
- S59
-
P.3.10 Ethanol-like effects of N-methyl-d-aspartatereceptors antagonist memantine, and its ability to prevent cue induced alcohol cravingTsoy, M. / Krupitsky, E. M. / Neznanova, O. N. / Burakov, A. M. / Didenko, T. Y. / Masalov, D. V. / Romanova, T. N. / Bespalov, A. Y. / Zvartau, E. E. / Krystal, J. et al. | 2005
- S61
-
P.3.13 Clinical impact of CYP2D6 polymorphismin patients with Alzheimer's disease in therapy with donepezilScordo, M. G. / Varsaldi, E. / Miglio, G. / Villa, M. L. / Biolcati, A. / Dahl, M. L. / Lombardie, G. et al. | 2005
- S62
-
P.3.14 Cholinergic modulation of memory, learning and visuospatial processes in healthy elderly volunteersWezenberg, E. / Verkes, R. J. / Sabbe, B. G. / Ruigt, G. S. / Hulstijn, W. et al. | 2005
- S64
-
P.3.17 Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the ÆSOP studyDazzan, P. / Morgan, K. D. / Orr, K. / Hutchinson, G. / Chitnis, X. / Suckling, J. / Fearon, P. / McGuire, P. K. / Mallett, R. M. / Jones, P. B. et al. | 2005
- S65
-
P.3.18 Early course of schizophrenic disorders;results from a Dutch epidemiological studyVeen, N. / Kahn, R. S. / Hoek, H. W. / Laan, W. / Schols, D. S. / van der Tweel, I. / Selten, J. P. et al. | 2005
- S66
-
P.3.20 An fMRI study of the effect ofmethylphenidate on neurocognitive function in children with ADHDHalari, R. / Taylor, E. / Smith, A. / Mohammad, M. / Brammer, M. / Rubia, K. et al. | 2005
- S67
-
P.3.21 The effect of clozapine on factorscontrolling glucose homeostasisHowes, O. D. / Bhatnagar, A. / Gaughran, E. P. / Amiel, S. / Murray, R. M. / Pilowsky, L. S. et al. | 2005
- S68
-
P.3.22 Predictive factors of resistance to antidepressant treatment: results from a European multicentre studyOswald, P. / Souery, D. / Kaspere, S. / Lecrubier, Y. / Zohar, J. / Mendlewicz, J. et al. | 2005
- S69
-
P.3.24 Volumes of brain structures in twinsdiscordant for bipolar disordervan der Schot, A. C. / Vonk, R. / Hulshoff Pol, H. E. / Nuboer, V. / Nolen, W. / Kahn, R. S. et al. | 2005
- S71
-
S.4.2 Bipolar disorderGoodwin, G. M. / Handley, W. A. et al. | 2005
- S72
-
P.4.01 A functional NOS-III haplotype is associated with bipolar disorderReif, A. / Strobel, A. / Jacob, C. P. / Fritzen, S. / Schmitt, A. / Lesch, K. P. et al. | 2005
- S74
-
P.4.04 Substitution of venlafaxine by fluoxetine and tianeptine in a conditioned taste aversion paradigmKayir, H. / Alici, T. / Uzbay, I. T. et al. | 2005
- S75
-
P.4.05 Morphologic changes of heart electric field in depressive patients treated with dosulepineKitzlerová / E. / Kittnar, O. / Paclt, I. / Slaví / ek, J. / Anders, M. / Dohnalová / A. et al. | 2005
- S77
-
P.4.08 Neurophysins response to apomorphineand clonidine in major depressionScantamburlo, G. / Hansenne, M. / Ansseau, M. / Legros, J. J. et al. | 2005
- S78
-
P.4.09 Behavioural and neurochemical consequencesof sIRNA-induced knockdown of serotonin and dopamine transporters in the adult mouse brain: Implications for validation of novel antidepressant targetsThakker, D. R. / Natte, F. / Hü / sken, D. / Maier, R. / van der Putten, H. / Hoyer, D. / Cryan, J. F. et al. | 2005
- S79
-
P.4.10 Different response to a dexamethasone and prednisolone test in treatment-resistant depressed patientsJuruena, M. F. / Cleare, A. / Papadopoulos, A. S. / Poon, L. / Lightman, S. / Pariante, C. M. et al. | 2005
- S81
-
Author index| 2005
- S85
-
Keyword index| 2005
- S87
-
Current status of genetics of bipolar disorderCraddock, N. et al. | 2005
- S89
-
Animal modeling of depressive disordersLeonard, B. E. et al. | 2005
- S299
-
Behavioral differences between alcohol-dependent mice forcibly treated or not treated with waterAkhundov, R. A. / Jafarov, F. I. / Khudaverdijev, A. S. et al. | 2005
- S315
-
S.01.04 Mood-stabilisers for schizophrenia| 2005
- S316
-
S.02.03 Course and outcome of rapid cycling bipolar disorder| 2005
- S317
-
S.03.01 Are protein alterations in schizophrenia due to early environmental insult?| 2005
- S318
-
S.03.04 Neuronal and endothelial nitric oxide synthase haplotypes are associated with endogenous psychoses| 2005
- S319
-
S.03.07 The role of corticotropin-releasing factor receptor subtypes in stress and monoaminergic neurotransmission| 2005
- S320
-
S.04.02 GABA-A subtype selective drugs as new treatments for anxiety| 2005
- S321
-
S.04.05 The anxiolytic-like effects of metabotropic glutamate receptor ligands| 2005
- S323
-
S.06.04 Genetic studies reveal atypical synaptic architectures in autism spectrum disorders| 2005
- S325
-
S.07.04 Role of the cannabinoid CB1 receptor antagonist SR 141716A in relapse to heroin-seeking| 2005
- S326
-
S.07.07 Predictive factors of resistance to antidepressant treatment: results from a European multicentre study| 2005
- S328
-
S.09.03 Social anxiety disorder: subtypes and spectrums| 2005
- S329
-
S.10.01 The endogenous opioids story| 2005
- S331
-
S.11.03 The neuropeptide galanin and its possible relevance for mood disorders| 2005
- S332
-
S.12.02 Genes and subtypes of schizophrenia| 2005
- S333
-
S.13.01 What outcomes, what interventions - the methodology| 2005
- S334
-
S.13.04 Maintenance treatment in bipolar disorder: evidence base and reality in clinical practice| 2005
- S335
-
S.14.02 Alcohol, nicotine, amphetamine and cocaine: the role of dopamine in drug self-administration in humans| 2005
- S336
-
S.14.05 Dopamine, motivation and reward: disentangling the gordian node| 2005
- S337
-
S.15.04 Stress hypo-responsiveness during pregnancy and parturition: involvement of noradrenergic mechanisms in rodents| 2005
- S338
-
S.16.03 Alpha-synuclein and Lewy body diseases| 2005
- S339
-
S.17.04 Neuroimaging in early onset depression: genetic and environmental contributions| 2005
- S340
-
S.18.02 Neuroimaging studies in smokers| 2005
- S341
-
S.18.05 Alcohol and dopamine function| 2005
- S342
-
S.19.03 The cortical gene expression profile as a phenotype in genetic association| 2005
- S345
-
S.21.02 Hypothesis: chronic experience of social defeat is important risk factor for schizophrenia| 2005
- S346
-
S.22.01 Familial vulnerability, temperament and psychopathology in preadolescents: both general and dimension-specific associations| 2005
- S347
-
S.22.05 Candidate genes of anxiety and depression: from mice and rats to men| 2005
- S348
-
S.23.03 Chronic mild stress to evaluate antidepressive onset of action in animals| 2005
- S349
-
S.24.02 Treatment of behavioural and psychological symptoms in dementia| 2005
- S350
-
S.24.05 Molecular genetics of Alzheimer dementia| 2005
- S351
-
S.25.03 ADHD: new views from brain imaging| 2005
- S352
-
S.26.01 Contribution of hallucinations, delusions and cognition to the schizophrenia endophenotype| 2005
- S353
-
S.26.05 Improving the definition of schizophrenia with neurocognitive measures| 2005
- S354
-
S.27.03 Functional genetic polymorphisms and emotion processing| 2005
- S355
-
S.27.05 Antidepressants and social interaction| 2005
- S359
-
E.02.02 State of the art and promise of vagus nerve stimulation (VNS) and deep brain stimulation (DBS) in treatment of refractory depression| 2005
- S360
-
E.03.02 Treatment resistant mania and depression| 2005
- S361
-
E.06.01 Treatment of nicotine dependence and cocaine addiction| 2005
- S364
-
P.1.004 Assessing benefits of aripiprazole in depressed and bipolar children and adolescents: a naturalistic retrospective chart review study| 2005
- S365
-
P.1.007 Neurosteroids in bipolar disorder and major depressive disorder: findings of a controlled study in women during the premenstrual phase| 2005
- S366
-
P.1.010 Effects of selective nNOS inhibitor TRIM on behaviour of mice after chronic ethanol inhalation and withdrawal| 2005
- S367
-
P.1.012 Effect of partial locus coeruleus denervation on amphetamine-induced exploratory behaviour, behavioural sensitization and D2 receptor function| 2005
- S368
-
P.1.014 The effect of milnacipran and tramadol-milnacipran combination on nociception in a rat model of neuropathic pain| 2005
- S369
-
P.1.016 Effects of endocannabinoid neurotransmission enhancers in the intracranial self-stimulation paradigm and the reinforcing actions of cocaine| 2005
- S370
-
P.1.019 Dopamine antagonists induce disruption of maternal behavior in white female rats| 2005
- S372
-
P.1.024 Effect of fluoxetine on ischemia-induced changes of brain derived neurotropic factor immunoreactivity and neuronal cell death in the hippocampus of the mongolian gerbil| 2005
- S373
-
P.1.026 Neurological soft signs, neuropsychological performances and functional cerebral activation during cognitive and motor inhibition tasks in young-aged patients with schizophrenia: a fMRI study| 2005
- S374
-
P.1.028 Electrical hypothesis of affective disorders: some similarities between depression and epilepsy| 2005
- S375
-
P.1.030 Emotional component alters pain response in β-amyloid model of alzheimer's disease in mice| 2005
- S376
-
P.1.032 Chronic psychosocial stress in mice decreases the severity of acute dextran sulfate sodium-induced colitis, but impairs regeneration| 2005
- S377
-
P.1.034 Modulation of aversive responses by α2-noradrenergic antagonism in meriones unguiculatus confronted with brazilian constrictor snakes| 2005
- S378
-
P.1.036 Role of GABAA receptors in the substantia nigra pars reticulata in rat turning behaviour| 2005
- S380
-
P.1.041 Sustained stress induces an antiinflammatory response in rat colon that counteracts initial colonic inflammation| 2005
- S383
-
P.1.048 Mu-opioid receptors are involved in the tolerance to nicotine antinociceptive effects| 2005
- S384
-
P.1.050 Differences of brain function in males and females during a selective attention task - an fMRI study in depressives and healthy controls| 2005
- S386
-
P.1.055 Comparison the effects of aqueous extract of thymus vulgaris, dexamethasone and stress on acute and chronic pains in mice| 2005
- S388
-
P.1.060 The role of serotonin and the prefrontal cortex in cognitive flexibility| 2005
- S389
-
P.1.063 SL65.0155, a 5HT4 partial agonist reverses memory deficits induced by β25–35 amyloid peptide icv administration in mice| 2005
- S391
-
P.2.002 Chronobiological abnormalities in seasonal affective disorder measured with actigraphy| 2005
- S392
-
P.2.005 Exposure to SSRIs may reduce the risk of suicide amongst elderly patients suffering from major depression| 2005
- S393
-
P.2.007 Ziprasidone in the treatment of major depression with psychotic features| 2005
- S394
-
P.2.010 Venlafaxine XR versus escitalopram treatment of major depressive disorder| 2005
- S395
-
P.2.012 Is mirtazapine in combination with perospirone efficacious in drug resistant depression? - assessment in vivo microdialysis (MD)| 2005
- S397
-
P.2.016 Acute dextro-amphetamine administration does not alter phosphoinositol metabolism in the brains of either humans or animals| 2005
- S398
-
P.2.018 Use of olanzapine in the treatment of bipolar mania, a naturalistic setting| 2005
- S399
-
P.2.020 Antidepressants: Lithuanian psychiatrists' opinion and agents impacting selection of the treatment approach| 2005
- S400
-
P.2.022 The effects of long term paroxetine therapy on the ability to work and the quality of life in depressed patients| 2005
- S401
-
P.2.024 Mirtazapine augmentation in treatment-resistant major depressive disorder: an open-label, six-week trial| 2005
- S402
-
P.2.026 Change in brain-derived neurotrophic factor immunoreactivity in nucleus accumbens following repetitive electroconvulsive shocks| 2005
- S403
-
P.2.029 Mirtazapine greatly alleviates the symptoms of fibromyalgia| 2005
- S404
-
P.2.031 Development and preliminary psychometric evaluation of the motivation and energy inventory - short form (MEI-SF)| 2005
- S405
-
P.2.033 Depressed inpatients as subjects in pharmacological treatment trial: are participants representative of patients in everyday clinical practice?| 2005
- S406
-
P.2.035 Olanzapine/fluoxetine combination versus lamotrigine for bipolar I depression| 2005
- S407
-
P.2.037 Prophylactic effect of lithium in bipolar disorder in relation to DRD1 and DAT genotypes| 2005
- S410
-
P.2.044 Efficacy of quetiapine in improving quality of life in patients with bipolar depression| 2005
- S411
-
P.2.047 Questioning the binding affinities of venlafaxine and duloxetine at the monoamine transporters| 2005
- S413
-
P.2.050 Clinical investigation on efficacy and safety of long term repetitive rapid rate TMS in comparison to ECT and to treatment only with antidepressive drugs| 2005
- S414
-
P.2.052 treatment resistant depression: different response to dexamethasone and prednisolone test| 2005
- S416
-
P.2.057 Confirmed clinical efficacy of agomelatine (25–50 mg) in major depression: two randomized, double blind, placebo-controlled studies| 2005
- S418
-
P.2.062 Resistant depression in older adults: an international study of risperidone augmentation| 2005
- S419
-
P.2.064 Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder| 2005
- S420
-
P.2.067 A multicenter, open, non-controlled study on the acceptability, efficacy and safety of mirtazapine orally disintegrating tablets, in patients with depression| 2005
- S421
-
P.2.069 Quetiapine for the treatment of bipolar II depression| 2005
- S423
-
P.2.074 Thyroid axis activity and suicidal behavior in depressed patients| 2005
- S424
-
P.2.076 Sleep disorders in anxious and depressive outpatients| 2005
- S425
-
P.2.078 Discontinuation symptoms in social anxiety disorder, general anxiety disorder, and major depressive disorder| 2005
- S426
-
P.2.081 Heart rate variability in patients with major depression and effects of antidepressant treatment with SSRI| 2005
- S428
-
P.2.086 Neuropeptide Y in plasma during physical exercise test in patients with major depressive disorder| 2005
- S429
-
P.2.088 Use of antidepressants in patients diagnosed with major depressive disorder and adjustment disorder| 2005
- S431
-
P.2.093 The early diagnose of the psychiatric side effects of interferon-alpha| 2005
- S432
-
P.2.095 Brain-derived neurotrophic factor as potential diagnostic biochemical marker of depressive state| 2005
- S434
-
P.2.099 Biochemical and pharmacological profile of antidepressant and antipsychotic compounds at human monoamine transporters| 2005
- S435
-
P.2.102 Effect of agomelatine on the sleep EEG in patients with major depressive disorder (MMD)| 2005
- S437
-
P.2.106 Duloxetine vs. placebo in the treatment of elderly patients with MDD| 2005
- S438
-
P.2.108 Psychiatric disorders and sexual dysfunctions| 2005
- S439
-
P.2.110 Plasma ANP and BNP during exercise in patients with major depressive disorder and in healthy controls| 2005
- S441
-
P.2.115 Mood disorders in long-term care residential facilities| 2005
- S442
-
P.2.118 Predictors of manic switch with antidepressant treatment in unipolar depression| 2005
- S443
-
P.2.120 Quetiapine augmentation in treatment-resistant depression| 2005
- S444
-
P.2.123 Basal prolactin level in female patients with treatment-resistant depression| 2005
- S445
-
P.2.125 Citalopram treatment increases quality of life in patients with chronic renal failure and depression: results from a preliminary study| 2005
- S448
-
P.2.132 Analysis of suicidality in adults treated with fluoxetine| 2005
- S449
-
P.2.134 Bupropion for the treatment of major depressive disorder characterized by loss of pleasure, interest and energy| 2005
- S450
-
P.2.137 Change in the treatment habits in group of patients with bipolar affective disorder-I over the 5-year period - retrospective survey| 2005
- S451
-
P.2.139 Subsyndromal symptoms in euthymic bipolar patients and effects on course & treatment| 2005
- S453
-
P.2.144 Rise and fall of antidepressants prescribing in the Netherlands: 1993–2002| 2005
- S454
-
P.2.146 Early symptomatic worsening during treatment with fluoxetine in major depression: prevalence and implications| 2005
- S456
-
P.3.003 Association between clozapine-induced weight gain and serotonin 5-HT2C receptor gene polymorphism in Korean schizophrenic patients| 2005
- S457
-
P.3.006 Polish version of MARS - new compliance scale for schizophrenic patients| 2005
- S459
-
P.3.012 Olanzapine-induced leucopenia and neutropenia a case report| 2005
- S460
-
P.3.014 Clinical and cognitive correlates of duration of untreated psychosis in patients with schizophrenia in korea| 2005
- S461
-
P.3.016 The influence of clozapine on platelet serotonin, monoamine oxidase and plasma serotonin levels: relationship with symptoms and cognition| 2005
- S463
-
P.3.021 Personality variables as predictors of behaviour in psychiatric intensive care: implications for diagnosis| 2005
- S465
-
P.3.026 Parenteral administration of olanzapine for schizophrenic patients with aggressive behaviour| 2005
- S466
-
P.3.028 A volumetric MRI study of thalamus and basal ganglia in patients with first-episode drug naive schizophrenia| 2005
- S467
-
P.3.030 Cochrane meta-analysis: antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms| 2005
- S468
-
P.3.033 The socio-economic profile of schizophrenic patients across a longitudinal study in France: are indirect costs measurements relevant in this population?| 2005
- S469
-
P.3.035 Autobiographical memory remediation therapy in stabilized schizophrenic patients: preliminary results| 2005
- S472
-
P.3.042 Haematological parameters in schizophrenic patients and effects of treatment| 2005
- S474
-
P.3.046 Change in prepulse inhibition after switching schizophrenic patients from zuclopenthixol to long-acting injectable risperidone| 2005
- S475
-
P.3.048 Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term controlled study| 2005
- S476
-
P.3.051 Amisulpride vs quetiapine in the treatment of delirium: a prospective randomized open trial| 2005
- S477
-
P.3.053 Clozapine doses before and after its sudden discontinuation| 2005
- S479
-
P.3.058 Lack of association of the GSK-3β T-50C polymorphism with schizophrenia| 2005
- S481
-
P.3.062 Switch from atypical APs to long-acting risperidone: patient perspective| 2005
- S482
-
P.3.065 Six-month incidence of diabetes among schizophrenic patients in Belgium| 2005
- S483
-
P.3.068 Prolactin screening in a naturalistic cohort of outpatients with schizophrenia in UK| 2005
- S484
-
P.3.070 Can measurement of glycosylated hemoglobin (HbA1c) be used to screen for diabetes in schizophrenic patients?| 2005
- S485
-
P.3.072 Bifeprunox: a novel partial agonist for the D2 receptor with antagonistic capabilities depending on dopaminergic tone| 2005
- S486
-
P.3.074 Bifeprunox: a novel atypical antipsychotic sharing dopamine D(2,3,4) receptor and serotonin 5-HT(1A) receptor affinities| 2005
- S487
-
P.3.076 Bifeprunox: a novel atypical antipsychotic with in vivo 5-HT1A receptor agonistic activity| 2005
- S490
-
P.3.083 Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications| 2005
- S491
-
P.3.085 Serum brain derived neurotrophic factor levels in schizophrenic patients treated with olanzapine and clozapine| 2005
- S492
-
P.3.087 Tolerability and effectiveness of quetiapine in inpatients with schizophrenia: results of the acute phase of the TESIS study| 2005
- S493
-
P.3.089 Antioxidant defence system in patients with a first psychotic episode. effect of antipsychotic treatment| 2005
- S494
-
P.3.092 A comparative study of haloperidol and clozapine on lipid peroxidation in human plasma (in vitro)| 2005
- S499
-
P.3.102 Social cognitive functioning in schizophrenic inpatients treated with typical and atypical antipsychotics| 2005
- S500
-
P.3.105 Olanzapine dose and weight gain| 2005
- S501
-
P.3.107 Safety and efficacy of clozapine/risperidone combination in the treatment-resistant schizophrenia| 2005
- S502
-
P.3.109 Blockade of D3 or activation of D1 dopamine receptors enhances ACh release and social memory in rats: relevance to cognitive symptoms in schizophrenia| 2005
- S503
-
P.3.111 Atypical antipsychotics associated with insulin resistance in New Zealand Maori| 2005
- S504
-
P.3.114 Association of 5-HT2A receptor polymorphisms with clinical outcome of risperidone in schizophrenic patients| 2005
- S505
-
P.3.117 High frequency repetitive transcranial magnetic stimulation in the treatment of negative symptoms of schizophrenia: case study| 2005
- S506
-
P.3.119 Association between free testosterone level and severity of negative symptoms in male schizophrenia| 2005
- S507
-
P.3.121 A comparison between rapidly disintegrating and conventional formulation risperidone tablets| 2005
- S508
-
P.3.122 Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients| 2005
- S510
-
P.3.127 A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia| 2005
- S511
-
P.3.130 A significant association between adrenoceptor α1a (84880 T-C) and repeated measured BMI in schizophrenic patients with exposure to antipsychotics| 2005
- S512
-
P.3.133 Risperidone long acting injectable in elderly psychotic patients: assessment of tolerability and efficacy| 2005
- S514
-
P.3.137 Amisulpride monotherapy in treatment resistant schizophrenia| 2005
- S515
-
P.3.139 The association between neuroleptic malignant syndrome and functional polymorphism of the MDR1| 2005
- S518
-
P.3.146 Comparison of the assessment of abstraction in multi-national schizophrenia trials| 2005
- S519
-
P.3.148 Necritizing enterocolitis after clozapine treatment| 2005
- S520
-
P.3.150 Chronic treatment of haloperidol decrease antioxidant activity and may cause hepatotoxicity, dose dependently| 2005
- S521
-
P.3.152 Atypical antipsychotic drugs, prolactin and reproductive hormones| 2005
- S522
-
P.3.156 Pattern mixture approach to comparing outcomes - of benefit in guideline development?| 2005
- S523
-
P.3.158 Principal component analysis differentiates the receptor binding profile of a novel series of antipsychotic candidates from current antipsychotic drugs| 2005
- S524
-
P.3.160 Auditory scene analysis and perceptual streaming in patients with schizophrenia| 2005
- S527
-
P.4.004 Role of GABA/benzodiazepine receptors of the dorsal periaqueductal grey and medial hypothalamus of rats in innate and conditioned anxiety responses| 2005
- S528
-
P.4.006 Exploring neurocognitive endophenotypes of obsessive compulsive spectrum disorders using tests of cognitive and motor inhibition| 2005
- S529
-
P.4.008 A study on quality of life of patient with panic disorder by korean version of the smith kline beecham ‘QOL’ scale (KvSBQOL)| 2005
- S530
-
P.4.011 Anxiolytic drugs decrease activation of NADPH-diaphorase positive neurons in rats exposed to a live predator| 2005
- S531
-
P.4.013 Influence of personality on behavioral and cardiovascular response to cholecystokinintetrapeptide in healthy volunteers| 2005
- S532
-
P.4.015 Efficacy of acute and extension treatment with self-administered cognitive behaviour therapy and sertraline in panic disorder| 2005
- S533
-
P.4.017 Basilar artery blood flow velocity changes in patients with panic disorder following 35% CO2 challenge| 2005
- S534
-
P.4.019 The prevelance of dental phobia and dental anxiety in panic disorder and the effect of antidepressant treatment| 2005
- S537
-
P.4.025 Tiagabine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study| 2005
- S538
-
P.4.027 NK1 receptor occupancy and anxiolytic-like effect of the novel NK1 receptor antagonist vestipitant (GW597599) in gerbil| 2005
- S539
-
P.4.029 Prediction of response to paroxetine and venlafaxine by serotonin related genes in obsessive-compulsive disorder| 2005
- S540
-
P.4.032 Time course effects of donepezil, ziprasidone or both drugs on motor activity, anxiolytic response, and short and long term memories in mice| 2005
- S541
-
P.4.034 Treatment of panic disorder with and without agoraphobia| 2005
- S542
-
P.4.036 The marble burying test in mice: can its predictive validity for anxiety be improved?| 2005
- S543
-
P.4.038 Heart rate variability in patient with panic disorder (PD): etiopathogenetic and clinical implications| 2005
- S544
-
P.4.040 Efficacy of rater training in non psychiatric clinical trials| 2005
- S549
-
P.4.050 Changes of heart rate variability after pharmacological treatment in panic disorder| 2005
- S550
-
P.4.052 In vitro pharmacological characterisation of a novel NK1 receptor antagonist, vestipitant (GW597599)| 2005
- S551
-
P.4.054 The benzodiazepine alprazolam reduces contextual fear but not cued fear-potentiated startle in humans| 2005
- S552
-
P.4.056 Using a generalized anxiety disorder disease state model to quantify the effects of effective diagnosis and treatment on overall remission rates| 2005
- S553
-
P.4.058 Smoking in first stages of panic disorder| 2005
- S554
-
P.4.060 Treatments received by primary care patients with comorbid generalized anxiety disorder and back pain| 2005
- S555
-
P.4.062 Prevalence of mental disorders among psychiatric drug users in general practice| 2005
- S557
-
P.5.002 Taurine in health care; in and off smoking and beyond| 2005
- S557
-
P.5.001 Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder| 2005
- S558
-
P.5.003 Quick of cognitive deficit and early diagnosis of dementia| 2005
- S560
-
P.5.008 Co-occurrence of increased libido and erectile dysfunction in men with Parkinson's disease| 2005
- S561
-
P.5.010 Effects of rivastigmine on learning and short memory retention in rats with hypoxia-induced model of amnesia| 2005
- S562
-
P.5.012 Syndrome of mild cognitive impairment: correlation with negative life events and ApoE4 genotype| 2005
- S564
-
P.5.016 Prevalence of tardive movement subsyndromes in southern region of Israel| 2005
- S565
-
P.5.019 Plasma levels of tumor necrosis factor-alpha (TNFα) in first-episode bipolar disorder and schizophrenia patients| 2005
- S566
-
P.5.021 Semax treatment effects in patients with postradiation brain lesion| 2005
- S567
-
P.5.025 Results of a randomised, placebo-controlled 6-month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe| 2005
- S568
-
P.5.027 Cognitive effects of SL650155, a 5HT4 receptor partial agonist, in animal models of amnesia| 2005
- S570
-
P.5.032 Basal metabolism in panic patients during a treatment with paroxetine| 2005
- S575
-
P.6.005 The implication of nociceptin in alterations of cerebal blood flow regulation following postnatal exposure to ethanol in rats| 2005
- S576
-
P.6.008 Effect of serotonergic nerves lesion in dorsal and median raphe nucleus on the development of tolerance to morphine analgesia in male rats| 2005
- S577
-
P.6.011 The effectiveness of memantine in alcohol withdrawal syndrome| 2005
- S579
-
P.6.016 Relationship between symptom dimension, neurocognitive functioning and CNR1 central cannabinoid receptor gene with susceptibility to schizophrenia and substance abuse| 2005
- S580
-
P.6.018 Could acamprosate (calcium acetylhomotaurinate) be related to body mass index of alcoholic patients with gamma aminobutyric acid AA α6 polymorphism?| 2005
- S581
-
P.6.020 Effects of N-nitro-L-arginine methyl ester on bromocriptine-induced locomotor sensitization in mice| 2005
- S582
-
P.6.023 The comparison of frequencies of aldehyde dehydrogenase 2 genotypes and A1 allele of dopamine D2 receptor gene in alcohol dependence patients| 2005
- S583
-
P.6.026 Ecstasy induces both initiation and expression of behavioural sensitization to its stimulatory effects in mice| 2005
- S584
-
P.6.028 Does repeated treatment with MDMA sensitize to its effects on agonistic behaviour in mice?| 2005
- S585
-
P.6.030 Altered brain activity in cannabis users during associative memory: an fMRI study| 2005
- S586
-
P.6.032 Pattern of drug use among opioid addicts with comorbid attention deficit hyperactivity disorder and conduct disorder| 2005
- S587
-
P.6.034 Cannabis use and the human reward system: an fMRI-study| 2005
- S588
-
P.6.036 Changes in psychiatric comorbidity among substance abusers: from 1997 to 2003| 2005
- S589
-
P.6.039 Is cigarette smoking a gateway drug to subsequent alcohol and illicit drug use disorders: a controlled study of youth with and without ADHD| 2005
- S590
-
P.6.041 Dopamine D2 receptor gene and drug abuse: prevalence of combined A1/A2 Taql A and C/C Ncol genotypes in alcohol- and heroin-dependent patients| 2005
- S591
-
P.6.043 Active versus passive administration of addictive drugs: regiospecific differences in long-term gene expression| 2005
- S592
-
P.7.001 Family-based and association studies of MAO-A and ADHD: preferential transmission of the long promoter-region repeat| 2005
- S594
-
P.7.005 Use of a biomarker of norepinephrine transporter (NET) inhibition to assess atomoxetine effects during clinically recommended dosing| 2005
- S595
-
P.7.008 Plasma homovanillic acid changes after weight recovery in adolescent anorexia nervosa| 2005
- S596
-
P.7.010 Changes in platelet monoamine oxidase activity, cholesterol levels and hyperactive behaviour over a period of three years in adolescents| 2005
- S597
-
P.7.012 Preliminary Dutch findings from attention deficit hyperactivity disorder observational research in Europe, symptom severity and treatment prescribed| 2005
- S600
-
P.7.019 Glycogen synthase kinase 3-beta (GSK-3β) gene and temperament dimensions in anorexia nervosa| 2005
- S601
-
P.7.022 An MRI study of the effect of familial risk for ADHD on the cerebellar vermis| 2005
- S602
-
P.7.024 A prospective open-label long-term treatment trial of risperidone monotherapy in children and adolescents with bipolar disorder| 2005
- S603
-
P.7.026 The relationship of blood lead levels and behaviors and cognitive functions in attention deficit hyperactivity disorder| 2005
- S604
-
P.7.028 Effect of caffeine on the reversed continuous performance test (R-CPT) in high impulsive individuals| 2005
- S606
-
P.7.033 Correlations between serum orexins A and B and BMI in anorexia nervosa| 2005
- S607
-
P.8.001 Atypical sexual parasomnia responding to low dose clonazepam| 2005
- S608
-
P.8.004 Effects of hyperhomocysteinemia on the system of haemostasis under stress| 2005
- S609
-
P.8.007 Altered melatonin function in pathological gambling| 2005
- S610
-
P.8.010 Test-retest reliability is a major psychometric issue for selecting rating scales in psychiatry and must be assessed by appropriate indexes| 2005
- S611
-
P.8.013 Weight disorders at psychiatric patients| 2005
- S612
-
P.8.015 Drug-induced sedation in healthy volunteers: different profiles for lorazepam, mirtazapine, olanzapine and haloperidol| 2005
- S614
-
P.8.020 Prenatal hypoxia evokes alterations of cell structure in hippocampus| 2005
- S615
-
P.8.022 The biological activity of neuromodulator - original analogue of c-terminal fragment of arginine-vasopressin| 2005
- S616
-
P.8.024 Study of analgesic effects of semax analogues depends on their structure| 2005
- S618
-
P.8.029 The local peripheral anti-hyperalgesic effect of carbamazepine and oxcarbazepine in a rat model of inflammatory hyperalgesia| 2005
- S619
-
P.8.031 Successful use of modafinil in delayed sleep phase syndrome| 2005
- S620
-
P.8.033 Escitalopam treatment of kleptomania: an open trial with double-blind discontinuation| 2005
- S621
-
P.8.036 Effects of self-perception and social support on the perception of stress in pregnancy and labour| 2005
- S622
-
P.8.038 The role of adenosine A1 receptors in the local peripheral anti-hyperalgesic effects of carbamazepine and oxcarbazepine| 2005
- S623
-
P.8.040 The involvement of GABAergic but not opioidergic mechanisms in the antihyperalgesic effects of carbamazepine and oxcarbazepine| 2005
- S624
-
P.8.042 Self-injuring tendencies in a controlled sample of anorexia nervosa| 2005
- S625
-
P.8.044 Escitalopram treatment of compulsive buying disorder: an open trial followed by double-blind discontinuation| 2005
- S627
-
P.8.048 Utilization of psychotropic drugs in Croatia 2001–2003: comparison with Scandinavian countries| 2005
- S628
-
P.8.051 Patients at risk of suicide in bipolar i disorder: prospective study of ten years| 2005
- S629
-
P.8.053 Did actual reform strategy of drug market improve the pharmacotherapy of mental disorders in montenegro?| 2005
- S630
-
P.8.057 Sleep in patients with obsessive compulsive disorder is not altered compared to healthy controls| 2005
- S631
-
P.8.059 A randomized, double-blind, placebocontrolled study of OROS methylphenidate in the treatment of adults with attentiondeficit/hyperactivity disorder| 2005
- S632
-
P.8.061 Transition from psychostimulants to atomoxetine in pediatric and adolescent patients with attention-deficit/hyperactivity disorder| 2005
- S633
-
P.8.063 Sex FX: estimation of normative values and comparison with values from patients with major depressive disorder| 2005
- S635
-
P.8.068 Efficacy and tolerability of pharmacological treatments for personality disorders: a meta-analysis| 2005
- S636
-
P.8.070 Escitalopram in the treatment of premenstrual dysphoric disorder| 2005
- S637
-
P.8.072 Effects of pretreatment with ibuprofen in post-electroconvulsive therapy headache| 2005
- S638
-
P.8.075 Reducing social distance and challenging police officers' stereotypes towards psychiatric patients and their families| 2005
- S639
-
P.8.077 Evaluation of sexual functions of schizophrenic patients under antipsychotics: multicentered, uninterventional, cross-sectional, epidemiologic study| 2005
- S640
-
P.8.080 Disturbed leptin, insulin and glucose interactions in eating disorders| 2005
- S643
-
P.8.087 Quality of life and subthreshold affective symptomatology| 2005
- S644
-
P.8.089 Quality of life in patients with leg ulcers| 2005
- S645
-
P.8.091 Evaluation of [11C]R116301 as a potential PET ligand for investigating NK1 receptors in human subjects| 2005
- S646
-
P.8.093 Galantamine for cognitive dysfunction in bipolar disorder: a case report| 2005
- S647
-
P.8.095 Personality disorders in long-term care residential facilities| 2005
- S648
-
P.8.097 Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects| 2005
- S649
-
P.8.100 Sarcoidosis, mental disorders and quality of life| 2005
- S650
-
P.8.102 Treatment of paranoia in geriatric age| 2005
- S655
-
C.05.03 Generalized anxiety disorder - what is the optimal treatment duration?| 2005
- S656
-
C.06.02 Clinical implications of today's unmet treatment need in generalized anxiety disorder| 2005
- S657
-
C.07.01 Better understanding the use of the atypical antipsychotics in bipolar depression: informing clinical practice| 2005
- S658
-
C.08.01 Optimising activity at dopamine receptors: the role of partial agonists| 2005
- S659
-
C.09.01 Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system| 2005
- S660
-
C.09.04 Efficacy/tolerance profile of agomelatine and practical use in depressed patients| 2005
- S661
-
C.10.03 Recognizing and managing treatment resistant depression| 2005
- S662
-
C.11.04 Between the poles: new strategies for the treatment of acute bipolar mania| 2005
- SS46
-
P.4.044 Association of dopamine transporter gene (DAT1) polymorphism with behavioral inhibition (BI) in korean anxiety disorder patients: preliminary study| 2005
- SS78
-
P.6.013 Effect of partial locus coeruleus denervation on behavioural sensitization to amphetamine and dopamine D2 receptor-G protein interaction in rats with high or low exploratory activity| 2005
-
Treatment of anxiety disordersBandelow, B. et al. | 2005
-
Is there still a place for benzodiazepines?Pini, S. et al. | 2005
-
Treatment of addictionLesch, O. M. et al. | 2005
-
Neurodegenerative diseases and oxidative stressEmerit, J. / Edeas, M. et al. | 2005
-
Anxiety affects the development of experimental pain-depressive syndromes in two rat modelsKrupina, N. A. / Orlova, I. N. / Khlebnikova, N. N. / Smirnova, V. S. / Grafova, V. N. / Kukushkin, M. L. / Rodina, V. I. et al. | 2005
-
Positive influence of new chemical agent fluoglizine on behaviour of male mice with anxiety/depression-like stateKovalenko, I. L. / Avgustinovich, D. F. / Sorokina, I. V. / Tolstikova, T. G. et al. | 2005
-
Central action of 9-[2-(4-isopropylphenoxy)ethyl] adenine on brain neurotransmissionAnanyeva, O. Y. / Onishchenko, N. V. et al. | 2005
-
Chronopharmacological resemblance of antidepressant and anxiolytic drugsBayer, E. V. / Arushanian, E. B. et al. | 2005
-
Regional oxidative metabolism as measured by cytochrome c oxidase histochemistry in rats with low or high exploratory activity: implications for depressionHarro, J. / Matrov, D. et al. | 2005
-
Paroxetine in heroin addiction treatmentRokhlina, M. L. / Kitkina, T. A. / Gubanov, G. A. et al. | 2005
-
Open comparative randomized study efficacy and tolerability of risperidone, olanzapine and quetiaine in acute maniaBelenkaya, D. V. / Kuzavkova, M. V. / Mosolov, S. N. et al. | 2005
-
Circulatory levels of catecholamines and serotonin in neuroleptic malignant syndromeMalin, D. / Spivak, B. / Vered, Y. / Kozyrev, V. / Ravilov, R. / Mosolov, S. et al. | 2005
-
Correlation between antipyrine metabolism and neuroleptic load in shizophrenic patientsZiganshina, L. E. / Vedernikova, O. O. / Kuchaeva, A. V. / Gatin, F. F. et al. | 2005
-
Sudden deaths among hospitalized psychiatric patientsBenatov, P. / Abramov, S. / Sirota, P. et al. | 2005
-
Efficacy of a psychoeducational program for weight gain control in patients taking olanzapineCastrogiovanni, S. / Simoncini, M. / Iovieno, N. / Cecconi, D. / Dell Agnello, G. / Donda, P. / Grazzini, S. / Rossi, A. / Mauri, M. et al. | 2005
-
Discriminative stimulus effects of cycloprolyl-glycinePetlyanina, E. V. et al. | 2005
-
Influence of the ACHT(4-10) analogue Semax on anxiety and analgesia induced by different stressorsVilensky, D. A. / Ivanova, D. M. / Levitskaya, N. G. / Andreeva, L. A. / Kamensky, A. A. / Myasoedov, N. F. et al. | 2005
-
Influence of Ladasten on monoamines level in Maudsley reactive and Maudsley non-reactive ratsVoronin, M. et al. | 2005
-
Pharmacological validation of a new model of anxiety in rats and mice - the Suok ("ropewalking") test: sensitivity to diazepam and pentylenetetrazoleKalueff, A. V. / Tuohimaa, P. et al. | 2005
-
Emotional stress induced dominant lethal mutations in mice which may be prevented by a tranquilizerDaugel-Dauge, N. O. / Durnev, A. D. et al. | 2005
-
Kinetic analysis of the process elimination after single and different schemes of multiple administration of cinazepam - a novel prodrug possessing psychotropic activityZhuk, O. V. / Zinkovsky, V. G. / Schukin, S. I. et al. | 2005
-
Results of clinical study of ladasten, a drug with stimulatory and anxiolytic activitySyunyakov, S. A. / Grishin, S. A. et al. | 2005
-
Phase-I investigation of selective anxiolytic afobazoleKolotilinskaya, N. V. / Badyshtov, B. A. / Makhnycheva, A. L. / Nadorov, S. A. / Yarkova, M. A. et al. | 2005
-
Clinical and neurophysiological efficacy of neurofeedback in the combined therapy of anxiety disorders resistant to psychopharmacotherapyBiriukova, E. V. / Timofeev, I. V. / Mosolov, S. N. et al. | 2005
-
Alprazolam: clinical dynamics in neurotic disordersKupriyanova, I. E. et al. | 2005
-
The sense of coherence, quality of life and symptoms of anxiety and depression in patients with cataractHyper-Ochalik, M. / Piekarska, K. / Poftorak, K. / Krupka-Matuszczyk, I. et al. | 2005
-
Optimization of new anxiolytic drug formulations on the basis of pharmacokinetic researchesZherdev, V. P. / Kolyvanov, G. B. et al. | 2005
-
Effects of Tyr-MIF-1 family of peptides on antinociception after immobilization stress in ratsBocheva, A. I. / Dzambazova-Maximova, E. B. / Logofetov, A. D. et al. | 2005
-
Embryonic serotonin deficiency changes activity of 5-HT3 receptors implicated in prolonged pain mediation in the formalin test in adults ratsButkevich, I. P. / Mikhailenko, V. A. / Leont eva, M. N. et al. | 2005
-
The hypertensive ISIAH rat strain offers promise in pharmacological research of arterial hypertension and aggressive behaviorMarkel, A. L. et al. | 2005
-
The effect of new N-acetyl-L-aspartic acid analogue on dopamine release and synthesis in the rat brainSergeyev, V. S. / Onishchenko, N. V. et al. | 2005
-
Autoimmune responses to proteins HLDF and S100b as pathogenic factors and molecular markers of cerebrovascular diseasesElistratova, E. I. / Yakovleval, N. E. / Sherstnev, V. V. / Denischuk, I. S. / Yurasov, V. V. / Kostanyan, I. A. / Shirokov, E. A. / Skvortzova, V. I. / Gruden, M. A. et al. | 2005
-
Autonomic and behavioral effects of intracerebroventricular injected CRFGourine, V. N. / Dvoretsky, D. P. / Polenov, S. A. / Poputnikov, D. M. / Melenchuk, E. V. / Azev, O. A. / Chumak, A. G. / Gourine, A. V. et al. | 2005
-
Chronopharmacology of drugs improving cognitive brain functionsArushanian, E. B. et al. | 2005
-
Early complex developmental diagnosis and early intervention programme for children born with very low birth weightGajewska, E. / Sobieska, M. / Samborski, W. et al. | 2005
-
Nootropic and anxiolytic effects on repeated functional disruptions of avoidance responses in ratsInozemtsev, A. N. / Garibova, T. L. / Kapitsa, I. G. / Voronina, T. A. et al. | 2005
-
Binding of regulatory neuropeptide [^3H]-Semax (MEHFPGP), labeled in terminal Pro, to plasma membranes of the rat forebrainV unova, T. V. / Shevchenko, K. V. / Shevchenko, V. P. / Bobrov, M. Y. / Bezuglov, V. V. / Myasoedov, N. F. et al. | 2005
-
Clinical pharmacological study of the novel peptide nootropic drug noopeptTeleshova, E. S. / Davydova, I. A. et al. | 2005
-
Individualizing dosage regimens of antiepileptic drugs: Multiple Model (MM) adaptive controlBondareva, I. B. / Jelliffe, R. W. et al. | 2005
-
Clinical encephalographic analysis of the use of nooclerin with patients suffering from epilepsyRogacheva, T. A. / Melnikova, T. C. / Krasnov, V. N. et al. | 2005
-
The efficacy of nootropics and antihypoxants in correction of posttraumatic disorders of the brainZarubina, I. P. / Nurmanbetova, F. N. / Shabanov, P. D. et al. | 2005
-
Effect of lamictal on EEG paroxysmal activity of the female rat brain in different stages of the oestrous cycleRider, F. K. / Voronina, T. A. / Avakian, G. N. / Burd, S. G. / Nerobkova, L. N. / Solomatin, Y. V. / Kalinina, T. S. / Volkova, A. V. et al. | 2005
-
Experimental pharmacological evaluation of Sydnocarb effects: comparisons with methamphetamineSavchenko, N. M. / Witkin, J. M. et al. | 2005
-
Citalopram in the treatment of alcohol dependenceNebarakova, T. P. / Basmanova, T. B. / Lobacheva, A. S. et al. | 2005
-
Aprotinin as a new drug for treatment of opiate withdrawal syndromeSudakov, S. K. / Rusakova, I. V. et al. | 2005
-
Evaluation of the influence of organospecific remedies from the peritoneal liquid on ethanol intoxication in laboratory micePozdeyev, N. M. / Ryabov, N. V. / Napalkov, A. N. / Kozachuk, A. B. et al. | 2005
-
Substance P affects alcohol intake by dopamine-dependent mechanism and displays altered reinforcing properties in ethanol-treated ratsNikolaev, S. V. / Bychkov, E. R. / Lebedev, A. A. / Shabanov, P. D. et al. | 2005
-
Inducible nitric oxide synthase in the locus coeruleus of human opiate addictsDyuizen, I. V. / Kurbatskii, R. A. / Dirlam, G. G. / Kozhemyako, V. B. / Zavgorodnyaya, M. S. et al. | 2005
-
LP.01 Depression from an evolutionary perspective| 2005
-
S.01.02 Transcranial magnetic stimulation in schizophrenia| 2005
-
S.03.05 Behavioural and neurochemical consequences of siRNA-induced knockdown of serotonin and dopamine transporters in the adult mouse brain: implications for validation of novel antidepressant targets| 2005
-
S.05.05 Ibogaine therapy| 2005
-
S.07.03 MAO-A genotype interaction with environment (psychosocial factors) and risk for criminality and alcohol related problems| 2005
-
S.07.06 Different response to a dexamethasone and prednisolone test in treatment-resistant depressed patients| 2005
-
S.15.02 Effects of pregnancy stress on neuroendocrine and behavioural parameters in lactating dams and daughters: an animal model of post partum depression| 2005
-
S.18.04 Does heroin release dopamine? A positron emission tomography study| 2005
-
S.23.05 Can genes control antidepressant response?| 2005
-
S.27.04 Emotional processing in mood disorders| 2005
-
E.04.02 Antidepressant drugs and suicide, consequences for prevention| 2005
-
P.1.006 Acute effect of tryptophan plus ethanol on the relationship between the dorsal raphe nucleus and frontal cortex serotonergic neuronal transmitters| 2005
-
P.1.013 Measurement of monoaminergic activity by drugs acting on adrenergic α2-receptors in rat hippocampus and primary visual cortex| 2005
-
P.1.025 Apomorphine challenge in healthy volunteers, measured by growth hormone response, AX-continuous performance task and acoustic startle response| 2005
-
P.1.038 Prevention of ATP depletion in brain induced by subacute stress by PPARg agonists| 2005
-
P.1.051 Importance of individual anatomical variability in repetitive transcranial magnetic stimulation research| 2005
-
P.1.052 Hippocampal atrophy and neuroplasticity in posttraumatic stress disorder| 2005
-
P.1.057 Serotonin transporter occupancy after application of escitalopram and citalopram to healthy volunteers assessed by SPECT and the novel radioligand [I123]ADAM| 2005
-
P.2.009 Mirtazapine orally disintegrating tablet (ODT) for the treatment of depressive patients with insomnia and anxiety symptoms| 2005
-
P.2.032 Symptoms of depression cross-sectional markers of bipolar-II disorder| 2005
-
P.2.038 Influence of pegylated interferon-alpha on the nitric oxide system in high-risk melanoma patients| 2005
-
P.2.077 The depression inventory development project: update on progress so far| 2005
-
P.2.089 Plasma oxytocin and anxiety in depressed patients| 2005
-
P.2.100 Escitalopram and suicidality in depression in adults| 2005
-
P.2.107 Comparing age and gender responses during treatment with venlafaxine and selective serotonin reuptake inhibitors| 2005
-
P.2.138 Are there any new developments in depression treatment?| 2005
-
P.2.143 A comparison of unipolar depression treatment using antidepressants alone versus using antidepressants in combination with quetiapine| 2005
-
P.3.024 Skin conductance levels identify two subgroups of schizophrenics with different conentration of N-acetylaspartate in the left cingulated gyrus| 2005
-
P.3.050 Association analysis of dopamine D2 receptor genetic variants and tardive dyskinesia in schizophrenia following long-term antipsychotic treatment| 2005
-
P.3.066 Long term maintenance of weight loss in patients with severe mental illness through a behavioural programme in UK| 2005
-
P.3.077 The prognostic of schizophrenia and atypical antipsychotics| 2005
-
P.3.128 Efficacy and safety of lower doses of aripiprazole in patients with acute relapse of schizophrenia| 2005
-
P.4.007 Sexual pleasure in patients with obsessive-compulsive disorder?| 2005
-
P.4.014 Activation of NADPH-diaphorase positive neurons in rats after exposure to a live predator: effects of clomipramine treatments| 2005
-
P.4.018 Manipulation of the cannabinoid system subserves extinction or reconsolidation of fear memories| 2005
-
P.4.024 Augmentation of SRI's with naltrexone in OCD patients. a double blind placebo control cross-over study| 2005
-
P.4.030 Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder| 2005
-
P.4.041 A 6-month study of venlafaxine XR versus placebo in the treatment of posttraumatic stress disorder| 2005
-
P.4.059 Sexual abuse and clinical features in panic disorder| 2005
-
P.6.014 Impact of drug abuse on cognitive functioning in schizophrenia| 2005
-
P.6.025 Serum proteomic analysis during nicotine self-administration, withdrawal, extinction and relapse in rats| 2005
-
P.7.006 Facial EMG and affect processing in pervasive developmental disorder| 2005
-
P.7.009 Ziprazidone among adolescents with overlapping OCD and Tourette's syndrome: pilot study| 2005
-
P.7.014 An association study of the impulsiveness and aggressiveness in adolescent prisoners with serotonin transporter gene promoter region polymorphism| 2005